Radiation treatment drug granted fast track status

Cleveland Biolabs' acute radiation syndrome drug, CBLB502, has received Fast Track status from the FDA. The drug, which would be used to treat patients who have been exposed to radiation from nuclear weapons or dirty bombs, completed Phase I testing in 2008. Release